Assessment of Tumor Growth Inhibition Metrics to Predict Overall Survival

Modeling and simulation is proposed to support drug development phase transitions in oncology. Longitudinal tumor-size data recorded in patients are modeled to inform treatment efficacy, and the tumor growth inhibition (TGI) metrics are related to clinical end points, e.g., overall survival.

Author(s): Laurent Claret, Rene Bruno

Year: August 1, 2014

Back to top